Topiramate extended-release - Upsher-Smith

Drug Profile

Topiramate extended-release - Upsher-Smith

Alternative Names: Qudexy XR; USL-255

Latest Information Update: 03 Apr 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Upsher-Smith
  • Class Antiepileptic drugs; Antimigraines; Hexoses; Ketoses; Neuroprotectants; Obesity therapies; Small molecules; Sulfonic acids
  • Mechanism of Action AMPA receptor antagonists; Carbonic anhydrase inhibitors; GABA A receptor agonists; Kainic acid receptor antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Lennox-Gastaut syndrome; Migraine; Partial epilepsies; Tonic-clonic epilepsy

Most Recent Events

  • 30 Mar 2017 Launched for Migraine (Prevention, In adolescents, In adults) in USA (PO)
  • 30 Mar 2017 Registered for Migraine (Prevention, In adults, In adolescents) in USA (PO)
  • 13 Jan 2017 Zydus Pharmaceuticals enters into settlement agreement with Upsher Smith related to Topiramate extended release capsules
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top